Malignant Pancreatic Glucagonoma

specific

A glucagon-producing neuroendocrine tumor arising from the alpha cells of the pancreas. It may be associated with necrolytic erythema migrans, diarrhea, diabetes, glossitis, weight loss, malabsorption, and anemia. It displays vascular invasion and metastasizes to other anatomic sites.

Centers

Active Trials

—

Cancer Funding

Top Centers for Malignant Pancreatic Glucagonoma(19)

Ranked by research excellence score (trials · grants · publications). Methodology →

#	Center	Active Trials	Cancer Funding	Score
1	Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive	—	—	52.6
2	UNC Lineberger Comprehensive Cancer CenterChapel Hill, NC NCI Comprehensive	—	—	52.6
3	Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive	—	—	52.6
4	Laura and Isaac Perlmutter Cancer Center at NYU Langone HealthNew York, NY NCI Comprehensive	—	—	52.6
5	Winship Cancer InstituteAtlanta, GA NCI Comprehensive	—	—	52.6
6	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive	—	—	52.6
7	City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive	—	—	52.6
8	USC Norris Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive	—	—	52.6
9	Moffitt Cancer CenterTampa, FL NCI Comprehensive	—	—	52.6
10	Case Comprehensive Cancer CenterCleveland, OH NCI Comprehensive	—	—	52.6
11	University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive	—	—	52.6
12	Cleveland Clinic Cancer CenterCleveland, OH	—	—	52.6
13	Holden Comprehensive Cancer CenterIowa City, IA NCI Comprehensive	—	—	52.6
14	University of Illinois Cancer CenterChicago, IL	—	—	52.6
15	Fox Chase Cancer CenterPhiladelphia, PA NCI Comprehensive	—	—	52.6
16	Cancer Center at IllinoisUrbana, IL	—	—	52.6
17	Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL	—	—	52.6
18	Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ	—	—	52.6
19	Princess Margaret Cancer CentreToronto, ON	—	—	52.6

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →